



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

March 31, 2005

FILE COPY

C. Elaine Jones, Ph. D.
GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park ,
North Carolina 27709-3398

Dear Dr. Jones and Mr. Zoffer:

Your petition, requesting the Food and Drug Administration to stay FDA decision regarding approval of abbreviated new drug applications (ANDAs) for generic versions of Flonase (fluticasone propionate), was received by this office on 03/25/2005. It was assigned docket number 2004P-0239/PSA1 and it was filed on 03/25/2005. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Jennie C. Butler, Director
Division of Dockets Management
Office of Management Programs
Office of Management

Cc: Mr. David M. Fox
Hogan & Hartson LLP

2004P.0239

ACK1